​

MacroGenics (MGNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MGNX Stock Forecast

MacroGenics (MGNX) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $2.50, with a high of $3.00 and a low of $2.00. This represents a 61.29% increase from the last price of $1.55.

- $4 $8 $12 $16 $20 High: $3 Avg: $2.5 Low: $2 Last Closed Price: $1.55

MGNX Stock Rating

MacroGenics stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (47.62%), 10 Hold (47.62%), 1 Sell (4.76%), and 0 Strong Sell (0.00%).

Buy
Total 21 1 10 10 0 Strong Sell Sell Hold Buy Strong Buy

MGNX Price Target Upside V Benchmarks

TypeNameUpside
StockMacroGenics61.29%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts126
Avg Price Target$3.00$2.50$5.50
Last Closing Price$1.55$1.55$1.55
Upside/Downside93.55%61.29%254.84%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25125--8
May, 25126--9
Apr, 25126--9
Mar, 25127--10
Feb, 25137--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 14, 2025Peter LawsonBarclays$3.00$1.5988.68%93.55%
Mar 25, 2025H.C. Wainwright$2.00$1.7911.73%29.03%
Aug 07, 2024Stephen WilleyStifel Nicolaus$6.00$3.3877.51%287.10%
Jul 31, 2024Silvan TuerkcanJMP Securities$8.00$5.2552.38%416.13%
Jul 31, 2024Mayank MamtaniB.Riley Financial$5.00$5.25-4.76%222.58%
Jul 29, 2024Peter LawsonBarclays$9.00$5.5562.16%480.65%
May 23, 2024Kaveri PohlmanBTIG$9.00$4.6394.38%480.65%
May 13, 2024Debjit ChattopadhyayH.C. Wainwright$4.00$4.38-8.68%158.06%
May 10, 2024Peter LawsonBarclays$14.00$14.67-4.57%803.23%
May 10, 2024Etzer DaroutBMO Capital$8.00$14.67-45.47%416.13%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 14, 2025BarclaysOverweightOverweighthold
Sep 18, 2024JMP SecuritiesMarket PerformMarket Performhold
Sep 18, 2024H.C. WainwrightNeutralNeutralhold
Sep 16, 2024Cowen & Co.HoldHoldhold
Aug 21, 2024H.C. WainwrightNeutralNeutralhold
Aug 15, 2024JMP SecuritiesMarket PerformMarket Performhold
Jul 31, 2024BTIGBuyNeutraldowngrade
Jul 31, 2024JMP SecuritiesOutperformOutperformhold
Jul 31, 2024GuggenheimAccumulateNeutraldowngrade
Jul 31, 2024B. RileyNeutraldowngrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.25$-3.18$-1.95$-0.15$-1.07----
Avg Forecast$-3.20$-3.25$-2.03$0.43$-1.20$-2.20$-1.87$-2.31$-2.32
High Forecast$-1.57$-1.59$-0.80$0.49$-1.02$-0.48$-0.55$-1.70$-0.16
Low Forecast$-4.97$-5.05$-3.38$0.29$-1.40$-3.47$-3.30$-2.92$-5.50
Surprise %-29.69%-2.15%-3.94%-134.88%-10.83%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$97.76M$75.64M$151.94M$58.75M$149.96M----
Avg Forecast$76.67M$83.89M$150.06M$80.88M$159.93M$77.97M$87.38M$76.42M$120.09M
High Forecast$109.33M$119.63M$226.35M$92.31M$172.05M$131.38M$88.48M$156.83M$246.44M
Low Forecast$46.57M$50.95M$79.99M$68.52M$144.41M$18.14M$86.27M$21.65M$34.02M
Surprise %27.51%-9.83%1.26%-27.37%-6.23%----

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-117.78M$-190.86M$-120.02M$-9.06M$-66.97M----
Avg Forecast$-145.55M$-145.85M$-195.63M$49.82M$-74.81M$-176.54M$-164.31M$-143.21M$-143.88M
High Forecast$-116.44M$-116.68M$-156.51M$59.78M$-62.92M$-29.78M$-34.34M$-105.55M$-9.83M
Low Forecast$-174.66M$-175.02M$-234.76M$39.85M$-86.70M$-215.05M$-204.28M$-180.87M$-340.67M
Surprise %-19.08%30.86%-38.65%-118.18%-10.49%----

MGNX Forecast FAQ

Is MacroGenics stock a buy?

MacroGenics stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 10 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that MacroGenics is a favorable investment for most analysts.

What is MacroGenics's price target?

MacroGenics's price target, set by 21 Wall Street analysts, averages $2.5 over the next 12 months. The price target range spans from $2 at the low end to $3 at the high end, suggesting a potential 61.29% change from the previous closing price of $1.55.

How does MacroGenics stock forecast compare to its benchmarks?

MacroGenics's stock forecast shows a 61.29% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for MacroGenics over the past three months?

  • June 2025: 12.50% Strong Buy, 25.00% Buy, 62.50% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 11.11% Strong Buy, 22.22% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 11.11% Strong Buy, 22.22% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is MacroGenics’s EPS forecast?

MacroGenics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.2, marking a 105.61% increase from the reported $-1.07 in 2024. Estimates for the following years are $-1.87 in 2026, $-2.31 in 2027, and $-2.32 in 2028.

What is MacroGenics’s revenue forecast?

MacroGenics's average annual revenue forecast for its fiscal year ending in December 2025 is $77.97M, reflecting a -48.00% decrease from the reported $149.96M in 2024. The forecast for 2026 is $87.38M, followed by $76.42M for 2027, and $120.09M for 2028.

What is MacroGenics’s net income forecast?

MacroGenics's net income forecast for the fiscal year ending in December 2025 stands at $-177M, representing an 163.63% increase from the reported $-66.966M in 2024. Projections indicate $-164M in 2026, $-143M in 2027, and $-144M in 2028.